Table 2.

Ongoing T-VEC trials in melanoma

Phase	N	Disease	Stage	Intervention	Outcome	Reference
I	30	Melanoma (9/30)	IIIB–IV	T-VEC at 106, 107, 108 pfu/mL	0% PR or CR	Hu et al20
II	50	Melanoma	IIIC–IV	T-VEC at 106 and 108 pfu/mL	ORR 26%	Senzer et al21
III	436	Melanoma	IIIB–IV	T-VEC at 106 and 108 pfu/mL	ORR 26.4%	Andtbacka et al15
Ib	19	Melanoma	IIIB–IV	T-VEC + ipilimumab	ORR 50%	Puzanov et al29,30
Ib	21	Melanoma	IIIB–IV	T-VEC + pembrolizumab	ORR 57%	Long et al31

Abbreviations: T-VEC, talimogene laherparepvec; PR, partial response; CR, complete response; ORR, overall response rate.